Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial

Gubanski, Michael; Johnsson, Anders; Fernebro, Eva; Kadar, Lianna; Karlberg, Ingegerd; Flygare, Petra; Berglund, Åke; Glimelius, Bengt; Lind, Pehr

doi:10.1007/s10120-010-0553-4

Cited by 23 publications

(7 citation statements)

References 24 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A fluoropyrimidine combined with a platinum is mostly used and was previously reported to provide a median overall survival within clinical trials of approximately 11 months [ 3 ]. Use of an anthracycline in the 1 st line setting provides some minor additional benefit and both docetaxel and irinotecan have been shown to have a role in the 1 st or 2 nd line treatment settings [ 4 - 7 ].…”

Section: Introductionmentioning

confidence: 99%

Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy

Hultman

Mahteme

Sundbom

et al. 2014

J Exp Clin Cancer Res

View full text Add to dashboard Cite

BackgroundThe choice of drugs for treatment of advanced gastric cancer (GC) is empirical. The purpose of the current study was to benchmark ex vivo the sensitivity of GC tumor cells from patients to standard cytotoxic and some newly introduced targeted drugs (TDs), as a basis for drug selection in the treatment of GC.MethodsTumor cell samples from patients with GC were analyzed for sensitivity to 5-fluorouracil, cisplatin, oxaliplatin, irinotecan, mitomycin C, doxorubicin and docetaxel as well as for the targeted drugs bortezomib, sorafenib, sunitinib and rapamycin using a short-term in vitro assay based on retention of viable tumor cells of fluorescent fluorescein. Samples of normal mononuclear cells, chronic lymphocytic leukemia, ovarian cancer and colorectal cancer were included for comparison.ResultsThe GC samples were essentially as sensitive to the standard drugs and the TDs as those from colorectal cancer whereas the ovarian cancer samples were more sensitive. The individual GC samples varied considerably in sensitivity to increasing concentrations of the clinically used standard drugs. In GC, cisplatin was cross-resistant to oxaliplatin and 5-fluorouracil which, on the other hand, was not cross-resistant to the other cytotoxic drugs. The activity of sunitinib did not obviously correlate to that of the standard drugs.ConclusionEx vivo assessment of drug sensitivity of tumor cells from patients with GC is feasible and may provide information that could be useful for selection of drugs for treatment. Drug sensitivity varies considerably between and within individual samples arguing for individualized selection of drugs for chemotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy

Hultman

Mahteme

Sundbom

et al. 2014

J Exp Clin Cancer Res

View full text Add to dashboard Cite

show abstract

“…Randomized trials have shown that the new-generation regimens using oxaliplatin, docetaxel, irinotecan, and paclitaxel prolonged the MOS of AGC patients from 5.7-9.6 months [22][23][24][25][26] to 9.2-12.8 months [7,[27][28][29] compared with older-generation regimens such as 5-FU, ADM, MMC, CDDP, and MTX. Trastuzumab has also been reported to increase the MOS of AGC patients who were positive for HER2 [30].…”

Section: Discussionmentioning

confidence: 98%

Low-dose, short-interval target vessel regional chemotherapy through the hepatic artery combined with transarterial embolization in gastric cancer patients with liver metastases after failure of first-line or second-line chemotherapy

Chen

Liu

et al. 2014

Anti-Cancer Drugs

View full text Add to dashboard Cite

The objective of this study is to evaluate the efficacy and safety of combining low-dose, short-interval target vessel regional chemotherapy delivered through the hepatic artery (TVRC) with transarterial embolization (TAE) in advanced gastric cancer (AGC) patients with liver metastases after failure of first-line or second-line chemotherapy. All AGC patients with hepatic metastases had an indwelling arterial catheter placed in the hepatic artery and hepatic metastases were embolized with ultrafluid lipiodol, followed by two to three TVRC treatments in one cycle. After 3 weeks, the efficacy of TVRC treatment was evaluated using computed tomography (CT) or MRI scans before starting the next cycle. Follow-up assessments were performed every 2 months. The patients received a median of 7 (2-33) TVRC treatments together with TAE. All 22 AGC patients received a total of 191 TVRC treatments, which included 80.1% FOLFOX, 11.0% FOLFIRI, and 8.9% DC treatments. The median time-to-progression was 5.97 months; the median survival time was 11.6 months; and the 1-year and 2-year survival rates were 45.5 and 9.1%, respectively. The median overall survival from the diagnosis of liver metastasis (mOS) was 19.3 months. The most common side effects were grade I-II of abdominal pain, nausea, and vomiting. Combining TAE and TVRC administration through the hepatic artery for AGC patients with liver metastases resulted in decreased overall dose of chemotherapy, alleviation of side effects, and increased QOL of patient. This approach can be used as salvage therapy for AGC patients with predominant liver metastases after failure of intravenous chemotherapy.

show abstract

“…The median OS with planned second-line therapy was close to 12 months (11.5 and 10.6 months) [73]. Another crossover study comparing ECX and FOLFIRI had a lower OS and also failed to demonstrate a difference in outcome by sequence (9.5 vs 9.7 months, respectively; p = 0.95), although FOLFIRI first-line provided longer TTF than ECX first-line therapy (4.2 vs 5.1 months, respectively; p = 0.008) [74].…”

Section: Reviewmentioning

confidence: 88%

Management of advanced gastric cancer

Price¹,

Shapiro

Segelov

et al. 2012

Expert Review of Gastroenterology & Hepatology

View full text Add to dashboard Cite

Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial

Cited by 23 publications

References 24 publications

Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy

Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy

Low-dose, short-interval target vessel regional chemotherapy through the hepatic artery combined with transarterial embolization in gastric cancer patients with liver metastases after failure of first-line or second-line chemotherapy

Management of advanced gastric cancer

Contact Info

Product

Resources

About